Watch YARW. Know when insiders buy.
One email the day a filing lands. Free.
YARW
Yarrow Bioscience, Inc.
22.27
−1.33 −5.64%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $59.5MP/E —DIV YIELD —FCF YIELD -55.71%REV TTM $570K +13.8%NET INCOME −$26.5MNET CASH $22.9M52W 16.40 – 46.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $97K | +15.5% | — | −$3.1M | −$3M | — | -3.51 | −$2M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $86K | −28.9% | — | −$3.8M | −$3.6M | — | -0.08 | −$4.1M | — | — | May 15 |
| Q2 2025 · Jun 30 | $69K | −65.2% | — | −$7.5M | −$5.8M | — | -6.73 | −$10.8M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | $202K | +106.1% | — | −$9.2M | −$8.6M | — | -0.20 | −$11.5M | — | — | May 15 |
| Q4 2024 · Dec 31derived | $84K | +10.5% | — | −$12.8M | −$12M | — | -0.28 | −$9M | — | — | Feb 27 |
| Q3 2024 · Sep 30 | $121K | +6.1% | — | −$13.1M | −$12.2M | — | -0.29 | −$8.5M | — | — | Nov 7 |
| Q2 2024 · Jun 30 | $198K | +46.7% | — | −$10.4M | −$9.4M | — | -0.22 | −$8.5M | — | — | Aug 14 |
| Q1 2024 · Mar 31 | $98K | −1.0% | — | −$7.4M | −$6.2M | — | -0.15 | −$8M | — | — | May 8 |
| Q4 2023 · Dec 31derived | $76K | — | — | −$6.8M | −$6.2M | — | 4.04 | −$5.1M | — | — | Mar 6 |
| Q3 2023 · Sep 30 | $114K | — | — | −$6.2M | −$6.6M | — | -2.01 | −$5.2M | — | — | Nov 7 |
| Q2 2023 · Jun 30 | $135K | — | — | −$10.3M | −$10.1M | — | -3.09 | −$9.6M | — | — | Aug 14 |
| Q1 2023 · Mar 31 | $99K | — | — | −$5.9M | −$5.6M | — | -1.74 | −$5.5M | — | — | May 9 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $570K | — | −$29.7M | −$26.5M | -4646.1% | -0.62 | −$33.1M | $0 | −$33.1M | — | — |
| FY2024 · to Dec 31 | $501K | — | −$43.6M | −$39.8M | -7950.9% | -0.93 | −$34M | $117K | −$34.1M | — | — |
| FY2023 · to Dec 31 | $424K | — | −$29.3M | −$28.5M | -6710.4% | -2.78 | −$25.3M | $0 | −$25.3M | — | — |
| FY2022 · to Dec 31 | $477K | — | −$34.3M | −$23.2M | -4865.8% | -7.28 | −$29.2M | — | — | — | — |
| FY2021 · to Dec 31 | $931K | -259.6% | −$38.9M | −$73.3M | -7876.4% | -25.64 | −$56.4M | $0 | −$56.4M | — | — |
| FY2020 · to Dec 31 | $21M | 93.4% | −$252.5M | −$255.6M | -1217.4% | 7.88 | −$137.1M | $113K | −$137.2M | — | — |
Every number comes from Yarrow Bioscience, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.